KCNQ1-deficient and KCNQ1-mutant human embryonic stem cell-derived cardiomyocytes for modeling QT prolongation

Stem Cell Res Ther. 2022 Jun 28;13(1):287. doi: 10.1186/s13287-022-02964-3.

Abstract

Background: The slowly activated delayed rectifier potassium current (IKs) mediated by the KCNQ1 gene is one of the main currents involved in repolarization. KCNQ1 mutation can result in long-QT syndrome type 1 (LQT1). IKs does not participate in repolarization in mice; thus, no good model is currently available for research on the mechanism of and drug screening for LQT1. In this study, we established a KCNQ1-deficient human cardiomyocyte (CM) model and performed a series of microelectrode array (MEA) detection experiments on KCNQ1-mutant CMs constructed in other studies to explore the pathogenic mechanism of KCNQ1 deletion and mutation and perform drug screening.

Method: KCNQ1 was knocked out in human embryonic stem cell (hESC) H9 line using the CRISPR/cas9 system. KCNQ1-deficient and KCNQ1-mutant hESCs were differentiated into CMs through a chemically defined differentiation protocol. Subsequently, high-throughput MEA analysis and drug intervention were performed to determine the electrophysiological characteristics of KCNQ1-deficient and KCNQ1-mutant CMs.

Results: During high-throughput MEA analysis, the electric field potential and action potential durations in KCNQ1-deficient CMs were significantly longer than those in wild-type CMs. KCNQ1-deficient CMs also showed an irregular rhythm. Furthermore, KCNQ1-deficient and KCNQ1-mutant CMs showed different responses to different drug treatments, which reflected the differences in their pathogenic mechanisms.

Conclusion: We established a human CM model with KCNQ1 deficiency showing a prolonged QT interval and an irregular heart rhythm. Further, we used various drugs to treat KCNQ1-deficient and KCNQ1-mutant CMs, and the three models showed different responses to these drugs. These models can be used as important tools for studying the different pathogenic mechanisms of KCNQ1 mutation and the relationship between the genotype and phenotype of KCNQ1, thereby facilitating drug development.

Keywords: CRISPR/cas9; Iks; KCNQ1; LQT; hESCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Human Embryonic Stem Cells* / metabolism
  • Human Embryonic Stem Cells* / pathology
  • Humans
  • KCNQ1 Potassium Channel* / deficiency
  • KCNQ1 Potassium Channel* / genetics
  • KCNQ1 Potassium Channel* / metabolism
  • Long QT Syndrome* / genetics
  • Long QT Syndrome* / metabolism
  • Long QT Syndrome* / pathology
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology

Substances

  • KCNQ1 Potassium Channel
  • KCNQ1 protein, human